Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Mini-Review on SARS-CoV-2 Infection and Neurological Manifestations: A Perspective

Author(s): Vishal Chavda, Arif Tasleem Jan and Dhananjay Yadav*

Volume 21, Issue 3, 2022

Published on: 06 July, 2021

Page: [210 - 216] Pages: 7

DOI: 10.2174/1871527320666210706103422

Price: $65

Abstract

The coronavirus, also known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus-19), with its rapid rate of transmission, has progressed with a great impact on respiratory function and mortality worldwide. The nasal cavity is the promising gateway of SARS-CoV-2 to reach the brain via systemic circulatory distribution. Recent reports have revealed that the loss of involuntary process of breathing control into the brainstem that results in death is a signal of neurological involvement. Early neurological symptoms, like loss of smell, convulsions, and ataxia, are the clues of the involvement of the central nervous system that makes the entry of SARS-CoV-2 further fatal and life-threatening, requiring artificial respiration and emergency admission in hospitals. Studies performed on patients infected with SARS-CoV-2 has revealed three-stage involvement of the Central Nervous System (CNS) in the progression of SARS-CoV-2 infection: Direct involvement of CNS with headache, ataxia, dizziness, altered or impaired consciousness, acute stroke or seizures as major symptoms, peripheral involvement with impaired taste, smell, vision, and altered nociception, and skeletal muscle impairment that includes skeletal muscle disorders leading to acute paralysis in a particular area of the body. In the previous era, most studied and researched viruses were beta coronavirus and mouse hepatitis virus, which were studied for acute and chronic encephalitis and Multiple Sclerosis (MS). Although the early symptoms of SARS-CoV are respiratory pathogenesis, the differential diagnosis should always be considered for neurological perspective to stop the mortalities.

Keywords: SARS-CoV-2, CNS, multiple sclerosis, betacoronavirus, mouse hepatitis virus, neurodegeneration.

« Previous Next »
Graphical Abstract

[1]
Thompson R. Pandemic potential of 2019-nCoV. Lancet Infect Dis 2020; 20(3): 280.
[http://dx.doi.org/10.1016/S1473-3099(20)30068-2] [PMID: 32043978]
[2]
Corman VM, Lienau J, Witzenrath M. Coronaviruses as the cause of respiratory infections. Internist (Berl) 2019; 60(11): 1136-45.
[http://dx.doi.org/10.1007/s00108-019-00671-5] [PMID: 31455974]
[3]
Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011; 81: 85-164.
[4]
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77(6): 683-90.
[5]
Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020; 87: 18-22.
[http://dx.doi.org/10.1016/j.bbi.2020.03.031] [PMID: 32240762]
[6]
Xiang P, Xu X, Gao L, Wang H, Xiong H, Li R. First case of 2019 novel coronavirus disease with Encephalitis. ChinaXiv 2020; 202003: 00015.
[7]
Schoeman D, Fielding BC. Coronavirus envelope protein: Current knowledge. Virol J 2019; 16(1): 69.
[http://dx.doi.org/10.1186/s12985-019-1182-0] [PMID: 31133031]
[8]
Lin C-W, Tsai F-J, Tsai C-H, et al. Anti-SARS coronavirus 3C- like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res 2005; 68(1): 36-42.
[http://dx.doi.org/10.1016/j.antiviral.2005.07.002] [PMID: 16115693]
[9]
Lai KN, Tsang KW, Seto WH, Ooi CG. Clinical, laboratory, and radiologic manifestation of SARS. Curr Infect Dis Rep 2004; 6(3): 213-9.
[http://dx.doi.org/10.1007/s11908-004-0011-8] [PMID: 15142485]
[10]
Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020; 382(26): 2574-6.
[http://dx.doi.org/10.1056/NEJMc2009191] [PMID: 32302082]
[11]
Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 2018; 12: 386-6.
[http://dx.doi.org/10.3389/fncel.2018.00386] [PMID: 30416428]
[12]
Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: A delayed pandemic? In: Neurología. 2020; 35: pp. (4)245-51.
[13]
van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3(6): e00473-12.
[http://dx.doi.org/10.1128/mBio.00473-12] [PMID: 23170002]
[14]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[15]
Yu W-B, Tang G-D, Zhang L, Corlett RT. Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS- CoV-2 / HCoV-19) using whole genomic data. Zool Res 2020; 41(3): 247-57.
[http://dx.doi.org/10.24272/j.issn.2095-8137.2020.022] [PMID: 32351056]
[16]
Xiong C, Jiang L, Chen Y, Jiang Q. Evolution and variation of 2019-novel coronavirus. BioRxiv 2020.
[17]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[18]
de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Roles of host gene and non-coding rna expression in virus infection. Springer 2017; pp. 1-42.
[19]
Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses 2019; 11(1): 41.
[http://dx.doi.org/10.3390/v11010041] [PMID: 30634396]
[20]
Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep 2020; 19: 100682-2.
[http://dx.doi.org/10.1016/j.genrep.2020.100682] [PMID: 32300673]
[21]
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382(16): 1564-7.
[http://dx.doi.org/10.1056/NEJMc2004973] [PMID: 32182409]
[22]
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]
[23]
Soufi GJ, Hekmatnia A, Nasrollahzadeh M, et al. SARS-CoV-2 (COVID-19): New discoveries and current challenges. Appl Sci (Basel) 2020; 10(10): 3641.
[http://dx.doi.org/10.3390/app10103641]
[24]
Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020; S0953-6205(0920): 30151-5.
[25]
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92(6): 552-5.
[http://dx.doi.org/10.1002/jmv.25728] [PMID: 32104915]
[26]
Abdennour L, Zeghal C, Deme M, Puybasset L. Interaction brain-lungs. Ann Fr Anesth Reanim. 2012; pp. e101-7.
[27]
Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. Cell Host Microbe 2013; 13(4): 379-93.
[http://dx.doi.org/10.1016/j.chom.2013.03.010] [PMID: 23601101]
[28]
Leber AL, Everhart K, Balada-Llasat J-M, et al. Multicenter evaluation of biofire film array mening it is/encephal it is panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol 2016; 54(9): 2251-61.
[http://dx.doi.org/10.1128/JCM.00730-16] [PMID: 27335149]
[29]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[30]
Reinhold AK, Rittner HL. Barrier function in the peripheral and central nervous system-a review. Pflugers Arch 2017; 469(1): 123-34.
[http://dx.doi.org/10.1007/s00424-016-1920-8] [PMID: 27957611]
[31]
Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: A retrospective case series study. MedRxiv 2020.
[32]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[33]
Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The disease and tools for detection. ACS Nano 2020; 14(4): 3822-35.
[http://dx.doi.org/10.1021/acsnano.0c02624] [PMID: 32223179]
[34]
Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4.
[http://dx.doi.org/10.1186/s40779-020-0233-6] [PMID: 32029004]
[35]
Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of patients with COVID-19: A systematic review. Infection prevention in practice 2020; 2(3): 100061.
[36]
Wu R, Wang L, Kuo HD, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep 2020; 6(3): 56-70.
[PMID: 32395418]
[37]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 323(18): 1824-36.
[PMID: 32282022]
[38]
Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10(5): 766-88.
[http://dx.doi.org/10.1016/j.apsb.2020.02.008] [PMID: 32292689]
[39]
Yang X-L, Yuan Y-L, Zhang J, Wang R-F, Ni L-Q. Exploring potential effect of Shengjiang San on SARS-CoV-2 based on network pharmacology and molecular docking. Chin Trad Herbal Drugs. 2020; pp. 1795-803.
[40]
Wu H, Wang J, Yang Y, et al. Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology. Acta Pharm Sin 2020; 55(3): 374-83.
[41]
Ding Y, Zeng L, Li R, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med 2017; 17(1): 130.
[http://dx.doi.org/10.1186/s12906-017-1585-7] [PMID: 28235408]
[42]
Huang L, Wang J, Xu R, Liu Z. Study on Mechanism of Huanglian Jiedu decoction in treating novel coronavirus pneumonia based on network pharmacology. Zhong Yao Cai 2020; 3: 779-85.
[43]
Xiang Y, Lyu W. Study on the mechanism of Xue’s Wuye Lugen decoction tea drink on the prevention and control of COVID-19 based on network pharmacology and molecular docking. J Hubei Univ Chin Med 2020; 3: 5-11.
[44]
Zhang F-R, Zhu N, Li Z-Y, Tang S-H. Intervention mechanism of Qingwen Baidu Yin on cytokine storm based on network pharmacology. China J Chin Mater Med 2020; 45(7): 1499-508.
[http://dx.doi.org/10.19540/j.cnki.cjcmm.20200305.401] [PMID: 32489026]
[45]
Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua jiehe he huxi zazhi= Chin J Tuberculosis Respir Dis 2020; 43: E002.
[http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.0002] [PMID: 32023685]
[46]
Duan J, Yan X, Guo X, et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun 2005; 333(1): 186-93.
[http://dx.doi.org/10.1016/j.bbrc.2005.05.089] [PMID: 15939399]
[47]
Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004; 31(1): 69-75.
[http://dx.doi.org/10.1016/j.jcv.2004.03.003] [PMID: 15288617]
[48]
Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005; 326(4): 905-8.
[http://dx.doi.org/10.1016/j.bbrc.2004.11.128] [PMID: 15607755]
[49]
Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004; 59(3): 252-6.
[http://dx.doi.org/10.1136/thorax.2003.012658] [PMID: 14985565]
[50]
Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004; 318(3): 719-25.
[http://dx.doi.org/10.1016/j.bbrc.2004.04.083] [PMID: 15144898]
[51]
Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol 2008; 53(4): 9-13.
[PMID: 18756809]
[52]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[53]
Scagnolari C, Vicenzi E, Bellomi F, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 2004; 9(6): 1003-11.
[PMID: 15651759]
[54]
Mali SN, Thorat BR, Chopade AR. A viewpoint on angiotensin- converting enzyme 2, anti-hypertensives and coronavirus disease 2019 (COVID-19). Infect Disord Drug Targets 2020.
[http://dx.doi.org/10.2174/1871526520666200511005546] [PMID: 32389117]
[55]
Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools. Virol Sin 2020; 35(3): 266-71.
[http://dx.doi.org/10.1007/s12250-020-00207-4] [PMID: 32125642]
[56]
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11(2): 216-28.
[http://dx.doi.org/10.14336/AD.2020.0228] [PMID: 32257537]
[57]
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int J Biol Sci 2020; 16(10): 1708-17.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID: 32226288]
[58]
Abourashed EA, El-Alfy AT, Khan IA, Walker L. Ephedra in perspective-a current review. Phytother Res 2003; 17(7): 703-12.
[http://dx.doi.org/10.1002/ptr.1337] [PMID: 12916063]
[59]
Li SY, Chen C, Zhang HQ, et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 2005; 67(1): 18-23.
[http://dx.doi.org/10.1016/j.antiviral.2005.02.007] [PMID: 15885816]
[60]
Cheng PW, Ng LT, Chiang LC, Lin CC. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol 2006; 33(7): 612-6.
[http://dx.doi.org/10.1111/j.1440-1681.2006.04415.x] [PMID: 16789928]
[61]
Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem 2010; 18(22): 7940-7.
[http://dx.doi.org/10.1016/j.bmc.2010.09.035] [PMID: 20934345]
[62]
Yu MS, Lee J, Lee JM, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett 2012; 22(12): 4049-54.
[http://dx.doi.org/10.1016/j.bmcl.2012.04.081] [PMID: 22578462]
[63]
Lau KM, Lee KM, Koon CM, et al. Immunomodulatory and anti-SARS activities of Houttuynia cordata. J Ethnopharmacol 2008; 118(1): 79-85.
[http://dx.doi.org/10.1016/j.jep.2008.03.018] [PMID: 18479853]
[64]
Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell 2020; 183(1): 16-27.e1.
[http://dx.doi.org/10.1016/j.cell.2020.08.028] [PMID: 32882182]
[65]
Ahmed MU, Hanif M, Ali MJ, et al. Neurological manifestations of covid-19 (SARS-CoV-2): A review. Front Neurol 2020; 11: 518.
[http://dx.doi.org/10.3389/fneur.2020.00518] [PMID: 32574248]
[66]
Nepal G, Rehrig JH, Shrestha GS, et al. Neurological manifestations of COVID-19: A systematic review. Crit Care 2020; 24(1): 421.
[http://dx.doi.org/10.1186/s13054-020-03121-z] [PMID: 32660520]
[67]
Wenting A, Gruters A, van Os Y, et al. COVID-19 neurological manifestations and underlying mechanisms: A scoping review. Front Psychiatry 2020; 11: 860.
[http://dx.doi.org/10.3389/fpsyt.2020.00860] [PMID: 32973590]
[68]
Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci 2020; 77: 8-12.
[http://dx.doi.org/10.1016/j.jocn.2020.05.017] [PMID: 32409215]

Rights & Permissions Print Cite
Article Metrics
57
1
© 2024 Bentham Science Publishers | Privacy Policy